Duato discusses the split of the business, dealing with the scrutiny brought about by lawsuits, and 2025 priorities.

Johnson & Johnson (JNJ) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

The healthcare leader is also an excellent income stock. Johnson & Johnson has increased its dividend payout for 62 ...

Johnson & Johnson (NYSE: JNJ) didn't have an exceptional 2024; in fact, it was one of the worst-performing stocks on the ...

Johnson & Johnson JNJ4.13%increase ... red down pointing triangle for about $15 billion, evidence of the pharmaceutical industry’s renewed interest in neuroscience bets with vast but unrealized ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

Pharmaceutical giant Johnson & Johnson grew its share prices by 4.14 percent to close at $152.89 apiece as investors took heart from an investment bank’s rating upgrade of the company.

Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the ...

Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15.

Budget 2025: Seeks to further amend notification No. 16/2017-Customs, dated the 20th April, 2017 so to exempt certain drugs for supply under Patient Assistance Programme run by specified ...

nor has Johnson & Johnson's stock market performance. Is the pharmaceutical giant still worth investing in? Some might describe Johnson & Johnson's business as boring, but sometimes, that's not ...